Form 8-K - Current report:
SEC Accession No. 0001193125-24-258537
Filing Date
2024-11-14
Accepted
2024-11-14 16:04:53
Documents
15
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d892744d8k.htm   iXBRL 8-K 24878
2 EX-99.1 d892744dex991.htm EX-99.1 56115
6 GRAPHIC g892744g1115004418744.jpg GRAPHIC 5370
  Complete submission text file 0001193125-24-258537.txt   218386

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20241114.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20241114_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20241114_pre.xml EX-101.PRE 11268
17 EXTRACTED XBRL INSTANCE DOCUMENT d892744d8k_htm.xml XML 3629
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 241461738
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)